The American drug authority, The FDA has approved the use of secukinumabi to adults with rheumatic polylialgia that have not responded sufficiently to cortichosteroids or tolerate the gradual reduction of their dose, the producer Novatitis announced on Tuesday.
Reumatic controversy is an inflammatory disease that mainly affects people over 50 years of age and can cause severe pain and rigidity in their shoulders, necks and hips.

In the clinical test of the third phase, about 41% of patients in the group that received the approved dose reached stable emissions in the 52nd week, compared to about 20% in the placebo group. Both groups followed up on gradual lowering of cortichosteroids. The European Union approved the use of this shepherd for rheumatialism in October.
Source Layer: Signal





